Document is current
Any future updates will be listed below
-
Authors
Correll, Christoph U. https://orcid.org/0000-0002-7254-5646
Tulliez, Sebastien
Heinrich, Maggie
Rudell, Katja
Girardi, Alessandra
Keefe, Richard https://orcid.org/0000-0002-0173-8897
Goldring, Abraham
Reuteman-Fowler, Corey
- License Information
-
More Information
Article History
Received: 29 November 2024
Accepted: 1 September 2025
First Online: 17 October 2025
Competing interests
: Christoph Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck, and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, and Rovi. He has received grant support from Boehringer-Ingelheim, Janssen, and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran. Sebastien Tulliez and Corey Reuteman-Fowler are employees of Boehringer Ingelheim. Maggie Heinrich, Katja Rudell, Alessandra Girardi, Richard Keefe, and Abraham Goldring provided independent consultancy activity for evaluation of the SCoRS and declare no other conflict of interest.
